Advertisement

Topics

AstraZeneca's Acalabrutinib gets priority review from FDA for mantle cell lymphoma

04:38 EDT 3 Aug 2017 | Pharmaceutical Business Review

AstraZeneca reported that the US Food and Drug Administration (FDA) has accepted and granted priority review for the New Drug Application (NDA) for its Bruton tyrosine kinase (BTK) inhibitor, acalabrutinib.

Original Article: AstraZeneca's Acalabrutinib gets priority review from FDA for mantle cell lymphoma

NEXT ARTICLE

More From BioPortfolio on "AstraZeneca's Acalabrutinib gets priority review from FDA for mantle cell lymphoma"

Quick Search
Advertisement
 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...